Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir | Zendy

Kulkunya Chokephaibulkit | Zendy; Maneeratn Nuntarukchaikul | Zendy; Wanatpreeya Phongsamart | Zendy; Orasri Wittawatmongkol | Zendy; Keswadee Lapphra | Zendy; Nirun Vanprapar | Zendy; Tim R. Cressey | Zendy

Open Access

Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir

Author(s) -

Kulkunya Chokephaibulkit,

Maneeratn Nuntarukchaikul,

Wanatpreeya Phongsamart,

Orasri Wittawatmongkol,

Keswadee Lapphra,

Nirun Vanprapar,

Tim R. Cressey

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks332

Subject(s) - lopinavir , lopinavir/ritonavir , ritonavir , medicine , pharmacokinetics , regimen , pharmacology , human immunodeficiency virus (hiv) , viral load , virology , antiretroviral therapy

Data on lopinavir/ritonavir tablets administered once daily in children are limited. We compared the pharmacokinetics (PK) of lopinavir/ritonavir twice daily versus once daily in virologically suppressed, HIV-infected children, and assessed the virological outcome, at 48 weeks, in children receiving the regimen of lopinavir/ritonavir once daily.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research